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Abstract Patients with diabetes are at high risk for 
polypharmacy (ie, use of multiple medications) for 
treatment of diabetes, associated comorbidities and other 
coexisting conditions. This study aims to estimate the 
prevalence of polypharmacy and factors associated with 
polypharmacy among adult patients with diabetes.
Methods A cross-sectional retrospective observational 
study of adults with diabetes, who visited the outpatient 
clinic of a tertiary teaching hospital in Saudi Arabia, was 
conducted. Data were extracted from the Electronic Health 
Record database for a period of 12 months (January–
December 2016). Polypharmacy was defined as the 
cumulative use of five or more medications. Polypharmacy 
among adults with diabetes was measured by calculating 
the average number of medications prescribed per patient. 
A multivariable logistic regression model was used to 
examine the factors associated with polypharmacy.
Results A total of 8932 adults with diabetes were 
included in this study. Of these, nearly 78% had 
polypharmacy which was more likely among women 
as compared with men and more likely among older 
adults (age ≥60 years) as compared with the adults. Also, 
polypharmacy was two times as likely among patients 
with coexisting cardiovascular conditions (adjusted OR 
(AOR)=2.89; 95% CI 2.54 to 3.29), respiratory disease 
(AOR=2.42; 95% CI 1.92 to 3.03) and mental health 
conditions (AOR=2.19; 95% CI 1.74 to 2.76), and 
three times as likely among patients with coexisting 
musculoskeletal disease (AOR=3.16; 95% CI 2.31 to 4.30) 
as compared with those without these coexisting chronic 
conditions categories.
Conclusions Polypharmacy is common among patients 
with diabetes, with an even higher rate in older adults 
patients. Healthcare providers can help in detecting 
polypharmacy and in providing recommendations 
for simplifying medication regimens and minimising 
medications to enhance the outcome of diabetes care.
IntRoduCtIon 
Diabetes is a highly prevalent chronic condi-
tion among adults in Saudi Arabia; between 
21% and 24% of adults are estimated to have 
diabetes.1 2 It is projected that 27% of adults 
in Saudi Arabia will have diabetes by 2035.3 
Diabetes is 1 of the top 10 causes of morbidity 
and mortality worldwide.4 Patients with 
diabetes often have coexisting chronic health 
conditions such as hypertension, dyslipi-
daemia, coronary artery disease, depression 
and chronic kidney disease, which requires 
the use of multiple medications to treat those 
coexisting chronic conditions.5 All of this put 
patients with diabetes at high risk of poly-
pharmacy,6 7 with an estimated prevalence 
of 57%–84% of patients with diabetes using 
five or more medications.8 A study among 
adults with diabetes in the USA documented 
that the 54% of adults with diabetes have 
polypharmacy.9 A multicentre cross-sectional 
survey conducted in Italy reported that 57% 
of patients with diabetes use five or more 
medications.10 In addition, polypharmacy was 
reported among 84% older adults patients 
with diabetes.8 In Saudi Arabia, a cross-sec-
tional study among 766 adults who visited 
outpatient’s clinic at a tertiary care centre, 
Strengths and limitations of this study
 ► This study has provided a real insight into the current 
prevalence and predictors of polypharmacy among 
patients with diabetes in Saudi Arabia including a 
large study population of patients with diabetes.
 ► Around 9000 patients were included in this study 
which allowed us to identify the prevalence of poly-
pharmacy among a subgroup of patients.
 ► This study has not controlled for the severity of di-
abetes using the Diabetes Complications Severity 
Index which may affect the rate of polypharmacy.
 ► This study used a 12-month period to measure mul-
tiple medications use which is not concurrent use 
and may have resulted in a very high rate of multiple 
medications uses.
 ► It has to be noticed that not all polypharmacy is 
harmful; however, future studies to assess inappro-
priate medications associated with polypharmacy is 
warranted.
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reported that the prevalence of polypharmacy among 
patients with diabetes was 71%.11 
An examination of polypharmacy among patients with 
diabetes is important because polypharmacy increases 
the probability of the adverse drug events,12 13 drug–drug 
interactions,14 duplication of therapy,15 decreases compli-
ance to antidiabetic medications16 and leads to suboptimal 
glycaemic control.17 The presence of polypharmacy is 
also associated with prescribing cascade, in which adverse 
drug events are misinterpreted as new medical condi-
tions which can result in the prescription of new medica-
tions to treat those conditions.18 Polypharmacy has other 
negative health consequences such as increased risk of 
hospitalisation and medication error,19 20 higher risk of 
fall,21 poor functional status,22 poor quality of life and 
high healthcare cost.23 24 Polypharmacy among patients 
with diabetes is often associated with many factors. These 
include age,11 sex,10 coexisting conditions,10 rurality,11 25 
diabetes complications10 and aggressive diabetes treat-
ment.26 27
To date, limited studies have examined the prevalence of 
polypharmacy among adults with diabetes living in Saudi 
Arabia on a large scale, and assessed the specific factors 
that put patients at risk of polypharmacy. Identifying the 
prevalence and the subgroup of patients at high risk of 
polypharmacy will facilitate pharmacovigilance efforts in 
clinical practice settings. Therefore, the primary objective 
of this observational study is to examine the prevalence 
of polypharmacy among adults with diabetes in Saudi 
Arabia and to identify the factors that are associated with 
polypharmacy, specifically the association between coex-
isting chronic conditions and polypharmacy.
MethodS
Study design
A cross-sectional retrospective observational study was 
conducted in a tertiary teaching hospital in Saudi Arabia. 
This hospital is one of the largest tertiary teaching hospi-
tals in Riyadh, Saudi Arabia, with a 1200-bed facility and 
all general and subspecialty medical services. The hospital 
provides primary, secondary and tertiary care services. 
The patient population is composed predominantly of 
local citizens as well as residents, from Northern region 
in Riyadh; the hospital also serves the entire country as a 
referral centre.
data source and data extraction
This study used data retrieved from the Electronic Health 
Record (EHR) database for the period from 1 January 
2016 to 30 December 2016. Strict confidentiality of the 
data was maintained throughout the research process. 
The data from EHR were derived from demographics 
file, clinical diagnosis file and prescription drug file. 
The demographics file contained information about the 
patients’ date of birth, gender, marital status, nation-
ality and encounter type. The clinical diagnosis file 
provided information about the clinical diagnosis from 
inpatient and outpatient visits. Physicians reported clin-
ical diagnosis using the International Classifications of 
Diseases, ninth edition, Clinical Modification (ICD-9-CM) 
codes, ICD-10th edition, CM codes or the Systematised 
Nomenclature of Medicine diagnosis codes. The prescrip-
tion drug file contained information about the medi-
cations used. The demographics, clinical diagnosis and 
prescription drug files were merged into one file using the 
encrypted patient medical record number. The complete-
ness and the validity of the data from EHR in this tertiary 
teaching hospital in Saudi Arabia has not been studied 
before; however, the researchers of this study examined 
the completeness of this data and found that 91.0% of 
the patients had a complete data (ie, have information 
on the age, gender, marital status, nationality, encounter 
type and clinical diagnosis) and 85.0% of the patients had 
complete medication-related information.
Study population
The study population comprised all adult patients with 
diabetes (type 1 and type 2) (age ≥18 year) (n=8932) who 
received their treatment at the outpatient’s setting in 
the tertiary teaching hospital during a 1-year period. No 
exclusion criteria were applied to the study population.
Patient and public involvement
Patients and public were not involved in the design or 
conduct of this study.
Measures
Dependent variable
In our study, the dependent variable was ‘polyphar-
macy’. There are different approaches in the literature to 
measure polypharmacy such as simultaneous, cumulative 
and continuous. Also, there is no consensus on the thresh-
olds regarding the number of medications above which we 
consider the existence of polypharmacy.28 In the current 
study, we defined polypharmacy as the cumulative use 
of five or more medications during a 1-year period, this 
threshold has been used more than others.25 28 29 Using 
this definition, the prevalence of polypharmacy among 
adults was measured by the sum of unique therapeutic 
medication classes administered over a 12-month period. 
There is no consensus on the medications that should be 
included in the measurements of the polypharmacy. Also, 
all the prescription and the non-prescription/over-the-
counter (OTC) medications categories were included in 
our definition of polypharmacy.
Independent variables
Independent variables included were age groups in years 
(18–29, 30–39, 40–49, 50–59, 60–69, 70–79, >80), gender, 
nationality (Saudi, non-Saudi), marital status (married, 
unmarried) and documented chronic conditions which 
were classified into five categories (cardiovascular, chronic 
kidney disease, musculoskeletal, respiratory or mental 
health conditions) (online supplementary appendix 1). 
Cardiovascular conditions composed of hypertension, 
ischaemic heart disease, vascular heart disease, stroke, 
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heart failure and dyslipidaemia. Musculoskeletal condi-
tions composed of osteoarthritis and osteoporosis; respi-
ratory conditions include asthma and chronic obstructive 
pulmonary disease (COPD). Mental health conditions 
include dementia, depression, anxiety and schizophrenia. 
These conditions have been selected because they are 
highly prevalent among patients with diabetes and some 
of them were associated with polypharmacy.5 30
Statistical analysis
Frequency and percentage were used to describe the cate-
gorical variables (age, sex, marital status, nationality, coex-
isting chronic conditions and polypharmacy). Mean and 
SD were used to describe continuous variables. χ2 tests were 
used to examine the factors associated with polypharmacy. 
A multivariable logistic regression was used to examine the 
factors associated with polypharmacy (ie, use of ≥5 medica-
tions) after adjusting for age, sex, marital status, nationality 
and coexisting chronic conditions. All statistical analyses 
were carried out using the SAS V.9.2.
ReSultS
A total of 8932 adult patients were identified during the 
12-month period. The majority were Saudi (89.4%), 
female (62.2%) and 43.3% of the study population were 
older adults (age ≥60 years), the mean age of the study 
population was 57 years old. About half of the subjects 
(54.1%) had two or more diagnosed coexisting chronic 
health conditions. Hypertension, dyslipidaemia, asthma, 
osteoarthritis and anxiety were among the most common 
chronic conditions in our study population. Characteris-
tics of the study population are presented in table 1.
Polypharmacy among patients with diabetes
Overall, 77.9% of adults with diabetes have used (cumu-
lative) five or more medications. Also, when we identified 
the rate of hyperpolypharmacy (ie, taking 10 or more 
medications), we found that 17.2% of adults have a hyper-
polypharmacy. The most commonly used medications 
in our study population were antidiabetic medications 
(81.4%), followed by non-steroidal anti-inflammatory 
drugs (NSAIDs) (72.4%) and antihyperlipidaemic agents 
(68.8%) (table 2).
The study population characteristics by polypharmacy 
status are summarised in table 1. This study found a 
significantly higher percentage of polypharmacy among 
older adults as compared with patients with age between 
18 and 29 years (84.8% vs 37.4%, p<0.001). Women 
with diabetes had a significantly higher percentage of 
polypharmacy as compared with men (81.7% vs 71.6%, 
p<0.001). Moreover, polypharmacy was significantly 
higher among patients with diabetes with two or more 
coexisting comorbid conditions versus those with no 
coexisting chronic conditions (89.6% vs 48.6%, p<0.001). 
Looking at comorbid conditions closely, polypharmacy 
was significantly higher among patients with cardiovas-
cular disease (83.4%, p<0.001), chronic kidney disease 
(95.2%, p<0.001), musculoskeletal (93.6%, p<0.001), 
respiratory (89.0%, p<0.001) and mental health condi-
tions (85.4%, p<0.001) as compared with those without 
those coexisting chronic conditions.
logistic regression: factors associated with polypharmacy
The adjusted ORs (AORs) and 95% CIs from multivari-
able logistic regression on polypharmacy are displayed in 
table 3. Several factors were identified: age, gender and 
coexisting chronic conditions. Polypharmacy was more 
likely among older adults as compared with younger 
adults. Women were more likely to have polypharmacy 
compared with men (AOR=1.60; 95% CI 1.43 to 1.79). 
Cardiovascular diseases, mental conditions, respiratory 
and musculoskeletal diseases were all significantly associ-
ated with polypharmacy. For example, adults with diabetes 
and musculoskeletal disease were three times more likely 
to have polypharmacy (AOR=3.16; 95% CI 2.31 to 4.30) as 
compared with adults with diabetes and without musculo-
skeletal conditions.
dISCuSSIon
Our study was set out to examine the prevalence of poly-
pharmacy among adults with diabetes in Saudi Arabia. In 
this large sample of subjects with diabetes, the rate of poly-
pharmacy was high, as nearly four out of five adults with 
diabetes were prescribed five or more medications. Similar 
rates were reported in the literature among patients with 
diabetes 54%–84%,8–10 however, to our knowledge, no 
study has attempted to measure the rate of polypharmacy 
among all age groups of adults with diabetes, which is a 
major contribution of our study. A higher rate of poly-
pharmacy among older individuals (age 60 and above) 
as compared with all age groups was also observed in this 
study. Studies among adults in the general population 
have reported that older adults (defined as age >60 or 
age >65 years) have a higher risk of polypharmacy use as 
compared with adults.31 32 One possible reason for the 
high rate of polypharmacy among this population is the 
coexistence of other chronic conditions.
Furthermore, a noteworthy finding of the current 
study is the high prevalence of chronic conditions and 
the higher rate of polypharmacy among diabetic individ-
uals with coexisting chronic conditions. Previous studies 
have shown that 90% of patients with diabetes had at least 
one coexisting chronic condition,5 our study found that 
86% of patients with diabetes had at least one coexisting 
chronic condition. It is plausible that the high rate of 
polypharmacy in this study is potentially associated with 
the number of comorbidities among the study popula-
tion. The findings of this study support that patients with 
diabetes with multiple chronic conditions were at higher 
risk of polypharmacy.5 33 Although there is a well-doc-
umented literature on the relationship between the 
higher number of coexisting conditions and polyphar-
macy,5 10 34 our study extended the literature by analysing 
the association between the type of chronic conditions 
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and polypharmacy. We observed that the polypharmacy 
rates differed by the type of coexisting chronic condi-
tions; with the highest use among those with musculoskel-
etal conditions. This is not surprising because individuals 
with musculoskeletal conditions such as osteoarthritis use 
analgesic and NSAIDs to relieve the chronic pain. We also 
observed that patients with cluster of diseases (diabetes 
and cardiovascular diseases) have a higher rate of poly-
pharmacy as compared with adults without the cluster 
of diseases which is consistent with the published litera-
ture.31 35 Patients with diabetes and mental health condi-
tions have also a high rate of polypharmacy as compared 
with those without mental health conditions. Further 
studies are required to explore the contributing factors, 
as there is no supporting evidence in the literature. Poly-
pharmacy was also highly prevalent among patients with 
diabetes and respiratory diseases, which is consistent with 
data from previous studies, which showed higher rates of 
medication use in patients with COPD.36
Accordingly, healthcare providers need to routinely 
monitor these individuals for potentially inappropriate 
medications, adverse drug events and drug–drug inter-
actions. For instance, in older individuals, comprehen-
sive geriatric assessment has shown effective impact in 
decreasing the number of medications prescribed.37 
Further, patients with diabetes and polypharmacy may 
benefit from multidisciplinary collaborative care model 
that involves pharmacist follow-up for the patients 
to assess the medication use and minimise polyphar-
macy. In an open-label, parallel-arm, randomised, 
controlled study, collaborative care has been associated 

















































































































































































































































































































































































































Table 2 Most prevalent therapeutic classes among the 
study population (n=8932)
Medication therapy class N %
  Oral antidiabetic agent 7270 81.4
  Non-steroidal anti-inflammatory drugs 6467 72.4
  Antihyperlipidaemic agents 6144 68.8
  Proton pump inhibitor 2540 28.4
  ACE inhibitor 2321 25.9
  Injectable antidiabetic agent 2253 25.2
  Calcium channel blocker 2162 24.2
  Corticosteroid, local 1892 21.1
  Diuretic 1934 21.6
  Beta-adrenergic blocker, beta-1 
selective
1806 20.2
  Angiotensin II receptor blocker 1796 20.1
  Thyroid analogue 1355 15.1
  Histamine H2 blocker 822 9.2
  Anticoagulants 706 7.9
  Corticosteroid, systemic 600 6.7
  Antiplatelet 357 4.0
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reduction the healthcare cost.38 Pharmacists can help 
other healthcare providers in detecting polypharmacy, 
drug interactions and in providing recommendations 
for simplified medication regimens and minimising 
medications to positively impact health outcomes of 
diabetes care.39 40
We also looked at other related factors for poly-
pharmacy. We observed that women were more likely 
to have a polypharmacy compared with men, this is 
consistent with the findings from data among patients 
with diabetes.10 In addition, studies have reported that 
women in the general population have a higher use of 
prescribed and non-prescribed medications, and higher 
healthcare utilisation as compared with men.41–44 This 
could be because women tend to be more concerned 
about their health and seek health services more often 
than men.45 It has to be noted that the majority of 
patients with diabetes in our study were women, this 
is not surprising since the rate of diabetes is higher in 
women as compared with men in Saudi Arabia.2
Strengths and limitations
This study has some limitations; we defined polyphar-
macy as the cumulative use of five or more medications 
during a 1-year period rather than the concurrent 
use of medications, using this definition may have 
overestimated the rate of polypharmacy. We did not 
control for the severity of diabetes using the Diabetes 
Complications Severity Index, which may affect the 
rate of polypharmacy. We have also only observed filled 
prescriptions and not actual use of the medications. By 
using the EHR data, we cannot eliminate some risk of 
bias; inaccurate information or missing data related to 
the use of EHR. Due to the cross-sectional nature of 
the data, it is difficult to assess any causal relationships. 
People with the end-of-life care were included in the 
study, which may have also overestimated the rate of 
polypharmacy.46 Moreover, we have included all thera-
peutic medication classes, including OTC medications 
and vitamins in our definition, which may have overes-
timated the rate of polypharmacy. It has to be noticed 
that not all polypharmacy is harmful; however, we have 
not assessed if the polypharmacy was appropriate or 
not. This study was conducted in a tertiary hospital in 
Riyadh; therefore, the findings from this study cannot 
be generalised to primary care settings or to other 
regions in Saudi Arabia. In addition, we cannot exclude 
selection bias; patients included in this study may be 
sicker, have sever diabetes and higher rates of comor-
bidities as compared with individuals seen in primary 
care settings.
Despite these limitations, this study has many advan-
tages such as the use of large sample size, which allowed 
us to identify the prevalence of polypharmacy among a 
subgroup of patients. Furthermore, findings from this 
study added to the existing literature on the prevalence 
of polypharmacy among all age groups and identified 
the individuals who have a high risk of polypharmacy 
based on their comorbidities. In addition, our results 
highlighted the need for routine monitoring of high-
risk individuals for drug-related problems. Therefore, 
future studies are required to identify the rate of poly-
pharmacy among other healthcare settings and assess 
the impact of pharmacist-led interventions on the rate 
of polypharmacy in patients with diabetes.
ConCluSIon
Polypharmacy is very common among adults with 
diabetes; particularly among individuals with multiple 
chronic conditions. Older adults patients have a 
higher rate of polypharmacy, which could be due to 
the increased number of multiple chronic conditions 
in this population. Moreover, patients with coexisting 
cardiovascular, mental and musculoskeletal chronic 
conditions are at a high risk of polypharmacy. Indi-
viduals with diabetes may benefit from simplified 
treatment regimens; thereby enhancing the health 
outcomes of this population.
Table 3 AORs and 95% CIs logistic regression on 
polypharmacy adults with diabetes, Electronic Health 
Records Database, 2016
AOR 95% CI Significance
Age group
  30–39 vs 18–29 1.48 (1.00 to 2.18) **
  40–49 vs 18–29 2.13 (1.47 to 3.08) ***
  50–59 vs 18–29 3.54 (2.46 to 5.11) ***
  60–69 vs 18–29 5.11 (3.51 to 7.44) ***
  70–79 vs 18–29 7.59 (5.07 to 11.35) ***
  >80 vs 18–29 9.65 (5.69 to 16.38) ***
Marital status
  Single versus married 1.16 (0.96 to 1.40)
Gender
  Female versus male 1.60 (1.43 to 1.79) ***
Nationality
  Non-Saudi versus Saudi 1.81 (1.50 to 2.19) ***
Cardiovascular conditions
  Yes versus no 2.89 (2.54 to 3.29) ***
Musculoskeletal conditions
  Yes versus no 3.16 (2.31 to 4.30) ***
Respiratory conditions
  Yes versus no 2.42 (1.92 to 3.03) ***
Mental health conditions
  Yes versus no 2.19 (1.74 to 2.76) ***
Based on 8932 adults with diabetes, who visited outpatient’s 
clinics from a tertiary hospital in 2016. Polypharmacy was defined 
as the cumulative use of five or more medications during the 
1-year period. 
Asterisks (*) represent significant differences on polypharmacy 
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ethics and data confidentiality
Confidentiality of the data was maintained throughout 
the research process. Retrieved data were stored and 
saved as coded excel files. A customised formula was 
used to generate the study-encrypted identification 
assigned to each participant and replaced patients’ 
medical record number. Data extracted were stored at 
the research unit at the tertiary hospital on secured, 
password-protected and limited accessed computers.
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